[1]王婉玲,杨　翠,高攀科,等.B细胞淋巴瘤/白血病-2基因、CD10和细胞周期蛋白D1在B细胞性非霍奇金淋巴瘤组织中的表达及意义[J].新乡医学院学报,2021,38(12):1128-1132.[doi:10.7683/xxyxyxb.2021.12.004]
　WANG Wanling,YANG Cui,GAO Panke,et al.Expression and significance of B-cell lymphoma/leukemia-2 gene,CD10 and cyclin D1 in B-cell non-Hodgkin′s lymphoma[J].Journal of Xinxiang Medical University,2021,38(12):1128-1132.[doi:10.7683/xxyxyxb.2021.12.004]
点击复制

B细胞淋巴瘤/白血病-2基因、CD10和细胞周期蛋白D1在B细胞性非霍奇金淋巴瘤组织中的表达及意义
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
38
期数:
2021年12
页码:
1128-1132
栏目:
临床研究
出版日期:
2021-12-05

文章信息/Info

Title:
Expression and significance of B-cell lymphoma/leukemia-2 gene,CD10 and cyclin D1 in B-cell non-Hodgkin′s lymphoma
作者:
王婉玲; 杨　翠; 高攀科; 陈小双; 梁勇会; 李敬东
(新乡医学院第一附属医院血液科，河南　卫辉　453100)
Author(s):
WANG Wanling; YANG Cui; GAO Panke; CHEN Xiaoshuang; LIANG Yonghui; LI Jingdong
(Department of Hematology,the First Affiliated Hospital of Xinxiang Medical University,Weihui 453100,Henan Province,China)
关键词:
B细胞性非霍奇金淋巴瘤; B细胞淋巴瘤/白血病-2基因; CD10; 细胞周期蛋白D1
Keywords:
B-cell non-Hodgkin′s lymphoma; B-cell lymphoma/leukemia-2 gene; CD10; cyclin D1
分类号:
R733
DOI:
10.7683/xxyxyxb.2021.12.004
文献标志码:
A
摘要:
目的　探讨B细胞淋巴瘤/白血病-2基因（Bcl-2）、CD10和细胞周期蛋白D1（cyclin D1）在B细胞性非霍奇金淋巴瘤（B-NHL）组织中的表达及临床意义。方法　选择2017年6月至2019年8月新乡医学院第一附属医院收治的78例B-NHL患者（B-NHL组）和50例淋巴组织反应性增生患者（对照组）为研究对象。取B-NHL组患者肿瘤组织和对照组患者反应性增生淋巴组织，采用免疫组织化学染色法检测Bcl-2、CD10及cyclin D1表达，比较2组患者Bcl-2、CD10及cyclin D1表达情况；收集B-NHL患者临床病历资料，分析Bcl-2、CD10和cyclin D1水平与B-NHL临床病理特征的关系；对B-NHL患者随访1 a，统计患者病死情况，采用单因素分析和logistic回归分析影响预后的因素。 结果　B-NHL组患者Bcl-2、CD10及cyclin D1阳性表达率分别为78.21%（61/78）、38.46%（30/78）、87.18%（68/78），对照组患者Bcl-2、CD10 及cyclin D1阳性表达率分别为36.00%（18/50）、100.00%（50/50）、0.00%（0/50）；B-NHL组患者Bcl-2、cyclin D1阳性表达率显著高于对照组（χ2=22.971、92.992，P＜0.01），CD10阳性表达率显著低于对照组（χ2=49.231，P＜0.01）。B-NHL患者的年龄、性别、肿瘤直径、肿瘤位置、临床分期与Bcl-2、CD10及cyclin D1阳性表达无关（P>0.05）；B-NHL患者的病理类型与CD10、cyclin D1阳性表达相关（P＜0.05），与Bcl-2阳性表达无关（P>0.05）。B-NHL组患者病死20例（25.64%），生存58例（74.36%）；肿瘤临床分期、病理类型、Bcl-2、CD10及cyclin D1表达与B-NHL患者病死相关（P＜0.05），年龄、性别、肿瘤直径、肿瘤位置与B-NHL患者病死无关（P>0.05）。Logistic回归分析结果显示，临床分期Ⅲ～Ⅳ期、病理类型为弥漫大B细胞淋巴瘤、Bcl-2阳性表达、cyclin D1阳性表达及CD10阴性表达是影响B-NHL患者死亡的独立危险因素（P＜0.01）。结论　Bcl-2、CD10及cyclin D1在B-NHL组织中异常表达，其可能参与了B-NHL的发生、发展；CD10、cyclin D1检测可鉴别诊断不同病理类型的B-NHL，且可作为评估B-NHL患者预后的参考指标。
Abstract:
Objective　To investigate the expression and clinical significance of B-cell lymphoma/leukemia-2 gene (Bcl-2),CD10 and cyclin D1 in B-cell non-Hodgkin′s lymphoma (B-NHL).Methods　A total of 78 B-NHL patients (B-NHL group) and 50 patients with reactive hyperplastic lymphoid tissue (control group) admitted to the First Affiliated Hospital of Xinxiang Medical University from June 2017 to August 2019 were selected as the study subjects.The expressions of Bcl-2,CD10 and cyclin D1 in tumor tissues of patients in the B-NHL group and reactive hyperplasia lymphoid tissues of patients in the control group were detected by immunohistochemical staining,and the expressions of Bcl-2,CD10 and cyclin D1 of patients were compared between the two groups.The clinical data of B-NHL patients were collected,and the relationships between the levels of Bcl-2,CD10,cyclin D1 and the clinical characteristics of B-NHL were analyzed.Patients with B-NHL were followed up for one year,and the death of patients was counted.Univariate analysis and logistic regression analysis were used to analyze the prognostic factors.Results　The positive expression rates of Bcl-2,CD10 and cyclin D1 of patients in the B-NHL group were 78.21%(61/78),38.46%(30/78) and 87.18%(68/78),respectively.The positive expression rates of Bcl-2,CD10 and cyclin D1 of patients in the control group were 36.00%(18/50),100.00% (50/50) and 0.00% (0/50),respectively.The positive expression rates of Bcl-2 and cyclin D1 of patients in the B-NHL group were significantly higher than those in control group (χ2=22.971,92.992;P<0.01),and the positive expression rate of CD10 was significantly lower than that in the control group (χ2=49.231,P<0.01).The age,gender,tumor diameter,tumor location,clinical stage were not related to the positive expression of Bcl-2,CD10 and cyclin D1 in B-NHL group (P>0.05);the pathological type was correlated with positive expression of CD10 and cyclin D1 in B-NHL patients (P<0.05),while the pathological type was not correlated with positive expression of Bcl-2 (P>0.05).In B-NHL group,20 (25.64%) patients died and 58(74.36%) patients survived.The clinical stage,pathological type,expression of Bcl-2,CD10 and cyclin D1 were correlated with death of patients with B-NHL (P<0.05),while age,gender,tumor diameter and tumor location were not correlated with death of patients with B-NHL (P>0.05).Logistic regression analysis showed that the clinical stage Ⅲ-Ⅳ,the pathological type of diffuse large B cell lymphoma,Bcl-2 positive expression,cyclin D1 positive expression and CD10 negative expression were independent risk factors affecting the death of B-NHL patients (P<0.01).Conclusion　The expression of Bcl-2,CD10 and cyclin D1 in B-NHL tissues are abnormal,which may participate in the occurrence and development of B-NHL.The detection of CD10 and cyclin D1 can diagnose the different pathological types of B-NHL,and can be used as reference indexto evaluate the prognosis of B-NHL patients.

参考文献/References:

［1］　王静,李馨筱,吴琳娜,等.弥漫性大B细胞淋巴瘤组织NF-κB/p65、Bcl-2和Bax表达及意义［J］.分子诊断与治疗杂志,2019,11(1):39-44.
［2］　HANEL W,TSYBA L,HUSZAR D,et al.Targeting hypersumoylation in mantle cell lymphoma ［J］.Blood,2019,134(Suppl 1):S4060.
［3］　王杰松,何鸿鸣,杨瑜,等.西达本胺治疗外周T细胞淋巴瘤的效果和安全性分析［J］.解放军医药杂志,2018,43(1):53-58.
［4］　KARKHANIS V,ALINARI L,OZER H G,et al.Protein arginine methyltransferase 5 represses tumor suppressor miRNAs that down-regulate CYCLIN D1 and c-MYC expression in aggressive B-cell lymphoma［J］.J Biol Chem,2020,295(5):1165-1180.
［5］　翁香琴.《流式细胞学在非霍奇金淋巴瘤诊断中的应用专家共识(2016年版)》解读［J］.临床血液学杂志,2017,30(5):687-692.
［6］　姜文瑞,杨方,吴运福.长链非编码RNA UCA1介导调控Wntβ-Catenin信号通路对NSCLS增殖,凋亡及侵袭性的研究［J］.医学分子生物学杂志,2019,16(4):303-309.
［7］　LI D M,JIANG Y P.Gastrointestinal involvement by mantle cell lymphoma observed by endoscopy:a case report［J］.Medicine,2017,96(11):e6321.
［8］　MALEK A,BHAGAT G.Cyclin D1-negative mantle cell lymphoma with aberrant CD3 expression［J］.Blood,2017,130(11):1388.
［9］　ASHIZAWA A T,GUTIERREZ-PUENTE Y,FORD R,et al.Abstract 5091:activity of Bcl-2 antisense therapeutic in aggressive non-Hodgkin′s lymphoma［J］.Cancer Res,2017,77(13 Suppl): S5091.
［10］　HEINE S,KLEIH M,GIMNEZ N,et al.Cyclin D1-CDK4 activity drives sensitivity to bortezomib in mantle cell lymphoma by blocking autophagy-mediated proteolysis of NOXA［J］.J Hematol Oncol,2018,11(1):112.
［11］　CHO B B,KELTING S M,GRU A A,et al.Cyclin D1 expression and polysomy in lymphocyte-predominant cells of nodular lymphocyte-predominant Hodgkin lymphoma［J］.Ann Diagn Pathol,2017,26:10-15.
［12］　MARTN-GARCIA D,NAVARRO A,RAFAL V,et al.CCND2 and CCND3 hijack immunoglobulin light-chain enhancers in cyclin D1- mantle cell lymphoma［J］.Blood,2019,133(9): 940-951.
［13］　陈坚,李苗,段相会,等.DLBCL患者CD68、cyclin D1蛋白表达和BCL-6基因重排及与生存期的相关性分析［J］.临床和实验医学杂志,2019,18(8):811-815.
［14］　张芬,罗东兰,陈玉,等.原发心脏CD5阳性且bcl-2、C-MYC双表达弥漫性大B细胞淋巴瘤临床病理学特征［J］.中华病理学杂志,2019,48(12):951-954.
［15］　MAURY S,CHEVRET S,THOMAS X,et al.Rituximab in B-lineage adult acute lymphoblastic leukemia［J］.New Engl J Med,2016,375(11):1044-1053.
［16］　袁振亚,王明华,翁阳.激活转录因子-2在非特指型弥漫大B细胞淋巴瘤中的表达及其与临床病理特征的关系［J］.广东医学,2020,41(6):575-579.

更新日期/Last Update: 2021-12-05